Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience
Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience
复制标题
Asunaprevir 和 daclatasvir 治疗肝移植后复发性丙型肝炎：日本多中心经验
DOI：
10.1111/ctr.13109
复制
发表时间：
2017
影响因子：
2.1
通讯作者：
Ohdan Hideki
中科院分区：
文献类型：
--
作者：
Ikegami Toru;Ueda Yoshihide;Akamatsu Nobuhisa;Ishiyama Kohei;Goto Ryoichi;Soyama Akihiko;Kuramitsu Kaori;Honda Masaki;Shinoda Masahiro;Yoshizumi Tomoharu;Okajima Hideaki;Kitagawa Yuko;Inomata Yukihiro;Ku Yonson;Eguchi Susumu;Taketomi Akinobu;Ohdan Hideki
在日本，尚未评估使用asunaprevir（ASV）和daclatasvir（DCV）的无IFN方案治疗肝移植（LT）后复发性丙型肝炎病毒（HCV）感染的安全性和疗效。对接受ASV-DCV治疗24周的复发性HCV基因型1b感染的LT受者（n = 74）进行了一项多中心研究。40名（54.1%）患者的病史对聚乙二醇干扰素和病毒唑（Peg-IFN/RBV）呈阳性，12名（16.2%）患者的病史对西米普韦（SMV）和Peg-IFN/RBV呈阳性。耐药相关变异体（RAV）在NS 3的D168（n = 1）和HCV基因组NS 5A区域的L31（n = 4）、Y 93（n = 4）和L31/Y 93（n = 1）处呈阳性。61例（82.4%）患者完成了24周治疗方案。尽管49例（80.3%）患者达到了持续病毒应答（SVR），但在有SMV治疗史的患者（n = 12）中仅2例（16.7%）达到了持续病毒应答。单变量分析显示，SMV病史（P< .01）和NS 5A突变（P= .02）是无SVR的重要因素。通过排除NS 3/NS 5A中有基于SMV的治疗或RAV病史的患者，SVR率为96.4%。通过排除NS 3/NS 5A中有SMV病史和RAV的患者，ASV-DCV的病毒清除率有利，SVR率较高。
The safety and efficacy of an IFN‐free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV‐DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg‐IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg‐IFN/RBV in 12 (16.2%) patients. Resistance‐associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty‐one (82.4%) patients completed the 24‐week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P< .01) and the presence of mutations in NS5A (P= .02) were the significant factors for no‐SVR. By excluding the patients with either a history of SMV‐based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV‐DCV was favorable, with a high SVR rate.
Asunaprevir/daclatasvir 和 sofosbuvir/ledipasvir 治疗活体肝移植后复发性丙型肝炎
影响因子：
4.2
作者：
K. Omichi;N. Akamatsu;Kazuhiro Mori;J. Togashi;J. Arita;J. Kaneko;K. Hasegawa;Y. Sakamoto;N. Kokudo
通讯作者：
N. Kokudo
影响因子：
29.4
作者：
Charlton, Michael;Everson, Gregory T.;Afdhal, Nezam
通讯作者：
Afdhal, Nezam